Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market. The ...

Bio-Rad claims that, Bio-Plex Pro magnetic bead-based human and mouse cytokine assays are multiplex assays that offer can fast performance for the detection of multiple biomarkers in a single ...

Bio-Rad Laboratories, Inc. announced the launch of five Droplet Digital™ PCR (ddPCR) Multiplex Mutation Screening Kits for detecting several key actionable cancer mutations and the wild-type allele in ...

In February 2021, the company received the FDA’s EUA for a COVID-19, influenza A and influenza B RT-PCR syndromic multiplex test. Earlier in January 2021, Bio-Rad received the FDA’s EUA for ...

This In Focus, supported by Bio-Rad Laboratories, will explore the challenges and advantages of multiplex PCR technologies and the tools being developed to overcome those challenges.

"The continued development of the Bio-Rad StarBright Dye portfolio, now totaling 28 dyes and spanning multiple lasers, gives researchers greater choice and flexibility across multiplex flow cytometry ...

Bio-Rad Laboratories introduces three new fluorescent dyes under the StarBright product range to support multicolor flow cytometry panels. In April 2022, Bio-Rad Laboratories introduced three new ...

The StarBright UltraViolet 510, StarBright UltraViolet 665, and StarBright UltraViolet 795 Dyes Offer Exceptional Brightness with Narrow Excitation and Emission Profiles to Support Multiplex Panels ...